l-S,R-buthionine sulfoximine: historical development and clinical issues

Add time:09/26/2019    Source:sciencedirect.com

l-S,R-buthionine sulfoximine (l-S,R BSO) is a potent specific inhibitor of γ-glutamylcysteine synthetase, the rate-limiting step in glutathione (GSH) biosynthesis. GSH is an important component of tumor drug resistance based on a strong association and recent transfection studies. Depletion of intracellular GSH by BSO significantly enhances the cytotoxicity of many cytotoxic agents, principally alkylating agents and platinating compounds but also irradiation and anthracyclines. Phase I clinical trials of BSO+melphalan (l-PAM)have been carried out and observed little toxicity with BSO alone and increased myelosuppression with BSO+l-PAM. Consistent and profound (<10% of control) GSH depletion was observed in serial determinations of tumor GSH levels in patients receiving continuous infusion (CI) BSO. Evidence of clinical activity has been observed in patients with alkylating or platinating agent-refractory tumors. Phase II evaluation of CI BSO with l-PAM is in progress.

We also recommend Trading Suppliers and Manufacturers of L-BUTHIONINE (cas 13073-21-7). Pls Click Website Link as below: cas 13073-21-7 suppliers

Prev:Thiol modulation and protectionPharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine
Next:Research reportSensory-motor performance after acute glutathione depletion by L-BUTHIONINE (cas 13073-21-7) sulfoximine injection into substantia nigra pars compacta)